Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.
Patients with relapsed aggressive lymphoma now survive significantly longer with newer treatments—two-year survival jumped from 29% to 43%.
The prognosis of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has been considered to be poor. OS significantly improved in Era 2 compared with Era 1 (HR=0.70, P=0.01), with 2-year OS of 43% versus 29%, respectively.
What the study was
- Study design
- Cohort study
- Population
- patients
- Sample size
- 134
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood advances
Why it surfaced
Score 6/10 [NOVEL_TREATMENT]: Cohort study (Journal Article) matched 'Hematologic malignancies'. Components — novelty:2/3, relevance:2/3, design:1/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.